



Institutional Biosafety Committee  
Meeting Minutes

Date: 04/24/2026 Start time: 12:00pm (ET) End time: 2:00pm (ET)

Advarra IBC meetings are closed to the public to protect confidential and proprietary information as outlined in the Advarra IBC standard operating procedures.

**Chair:** Nichole Tower

**Voting Members Present:** Dan Eisenman (Committee Member), Scott Swindle (Committee Member), Darlene Ward (Committee Member), Warren Rummage (Committee Member), Alain Houmeidan (Committee Member), Paul Gulig (Committee Member), Jenna Mckenzie (Committee Member), Mark Fields (Committee Member), Shannon Benjamin (Committee Member), Evelyn Fry (Community Member)

**Other Persons Present:** [REDACTED]

**Conflict of Interest:** The IBC Chair queried the IBC to identify any potential conflicts of interest and requested that any potential conflicts of interest be disclosed to the IBC. The IBC Chair then reminded the IBC that if any potential conflicts of interest were identified as the meeting progressed, disclosure would need to occur at that time. Identified potential conflict of interest:  Yes  No

Study Summary Information for Minutes			
<b>Protocol #</b>	[REDACTED]	<b>IBC Study Submission ID #</b>	PROTO202400152
<b>Study Title</b>	A Phase 3, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of [REDACTED] a Multivalent Candidate Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults ≥18 Years of Age		
<b>Agent</b>	lipid nanoparticle encapsulated mRNA		
<b>Agent Characteristics</b>	lipid nanoparticle encapsulated mRNA		
<b>rDNA Category</b>	III-C-1		
<b>Description of Recombinant Nucleic Acid Sources</b>	• mRNAs encoding [REDACTED]		

<b>Description of Genetically Modified Microbes or Vectors</b>	<ul style="list-style-type: none"> <li>N/A</li> </ul>				
<b>Description of Transgene Expression</b>	<ul style="list-style-type: none"> <li>mRNAs encoding [REDACTED]</li> </ul>				
<b>Risk Assessment of Procedures</b>	<ul style="list-style-type: none"> <li>Delivered intramuscularly <ul style="list-style-type: none"> <li>Sharps Safety</li> <li>Standard Precautions</li> </ul> </li> <li>All materials disposed of as biohazardous waste</li> </ul>				
<b>Site Information</b>					
<b>Site Name</b>	DM Clinical Research - Irving, TX	<b>IBC Site Submission ID #</b>	AMEND202600364		
<b>PI Name</b>	Mustafa Alibhai				
<b>Site Biosafety Level</b>	BSL2				
<b>Staff Training Verified by PI Signed SOP</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No				
<b>Amendment Summary</b>	PI Change from Heather Myers to Mustafa Alibhai				
<b>Motions, Votes, and Committee's Decision</b>					
<b>Motion:</b> Approve					
<b>Conditions:</b> N/A					
<b>Motion</b>	<b>First:</b> [REDACTED]		<b>Second:</b> [REDACTED]		
<b>Votes</b>	<b>For:</b> 11	<b>Against:</b> 0	<b>Recused:</b> 0	<b>Absent:</b> 0	<b>Abstained:</b> 0

**Chair Signature**

**Approved by Chair:**

**Name:** Nichole Tower

**Date:** 2026/05/05